Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 15/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 15/20 | 0.42 |
| ▸ | CASP1 | P29466 | 14/20 | 0.42 |
| ▸ | CASP7 | P55210 | 13/20 | 0.42 |
| ▸ | HPGD | P15428 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.38 |
| ▸ | GLA | P06280 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13740980 | 0.86 | POLB (0.58) | SMN1; SMN2POLBALDH1A1KDM4ETP53 | |
| SCHEMBL9685225 | 0.77 | MKNK2 (0.51) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL10519806 | 0.77 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10CASP1 | |
| SCHEMBL22720338 | 0.74 | SMN1; SMN2 (0.76) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL25677916 | 0.72 | HTR2C (0.56) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL8898686 | 0.72 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 | |
| Hydrochloric Acid SCHEMBL8898072 | 0.71 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL23282512 | 0.70 | OGA (0.48) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL1847339 | 0.69 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10CASP1 | |
| Hydrochloric Acid SCHEMBL31633382 | 0.69 | USP2 (0.53) | SMN1; SMN2POLBALDH1A1CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885POLB 1699/4885ALDH1A1 3370/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885POLB 1699/4885ALDH1A1 3370/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885POLB 1699/4885ALDH1A1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.